Výsledky vyhledávání - "Anaelys, Maceo"

A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors

Autor: Maribel G, Vallespi, Braulio, Mestre, Maria A, Marrero, Rolando, Uranga, Diana, Rey, Martha, Lugiollo, Mircea, Betancourt, Kirenia, Silva, Danay, Corrales, Yanet, Lamadrid, Yamilka, Rodriguez, Anaelys, Maceo, Pedro P, Chaviano, Gilda, Lemos, Ania, Cabrales, Freya M, Freyre, Hector, Santana, Hilda E, Garay, Brizaida, Oliva, Julio R, Fernandez

Publikováno v: International journal of cancerREFERENCES. 149(6)

CIGB-552 is a synthetic peptide that interacts with COMMD1 and upregulates its protein levels. The objectives of this phase I study were safety, pharmacokinetic profile, evaluation of the lymphocytes CD4+ and CD8+ and preliminary activity in patients

Vyhledávací nástroje:

Upřesnit hledání